in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Mylan to Buy Merck KGaA’s Generics Unit for $6.7 Billion
1:39 PM MDT | July 25, 2007 | Alex Scott
Mylan Laboratories (Canonsburg, PA) says it has agreed to buy Merck KGaA’s generic pharmaceuticals business for €4.9 billion ($6.7 billion) in cash. The sale price is in line with market expectations (CW, May 9, p. 6). Merck KGaA’s generics unit generated sales in 2006 of €1.8 billion, placing it fourth in the market behind Barr Pharmaceuticals (Woodcliff Lake, NJ), Novartis, and Teva Pharmaceutical Industries (Petach Tikva, Israel). Mylan and the Merck KGaA business will have a combined annual Ebitda of about $1 billion and sales of about...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee